Endurance Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-290
Closed -$25K 630
2020
Q3
$25K Sell
290
-35
-11% -$3.03K ﹤0.01% 368
2020
Q2
$28K Hold
325
﹤0.01% 365
2020
Q1
$27K Sell
325
-168
-34% -$15K 0.01% 340
2019
Q4
$47K Buy
493
+168
+52% +$15.1K 0.01% 288
2019
Q3
$28K Sell
325
-8,000
-96% -$718K ﹤0.01% 329
2019
Q2
$760K Buy
8,325
+7,962
+2,193% +$674K 0.12% 109
2019
Q1
$31K Sell
363
-4,464
-92% -$358K 0.01% 300
2018
Q4
$371K Buy
4,827
+4,788
+12,277% +$373K 0.07% 136
2018
Q3
$3K Hold
39
﹤0.01% 447
2018
Q2
$3K Sell
39
-1,283
-97% -$88.5K ﹤0.01% 457
2018
Q1
$96K Hold
1,322
0.02% 226
2017
Q4
$99K Hold
1,322
0.02% 218
2017
Q3
$102K Hold
1,322
0.02% 217
2017
Q2
$99K Hold
1,322
0.02% 224
2017
Q1
$88K Hold
1,322
0.02% 227
2016
Q4
$86K Hold
1,322
0.02% 229
2016
Q3
$92K Hold
1,322
0.02% 224
2016
Q2
$98K Sell
1,322
-525
-28% -$36.3K 0.02% 213
2016
Q1
$120K Hold
1,847
0.02% 200
2015
Q4
$142K Sell
1,847
-335
-15% -$26.6K 0.03% 188
2015
Q3
$181K Hold
2,182
0.03% 174
2015
Q2
$192K Sell
2,182
-1,116
-34% -$102K 0.03% 162
2015
Q1
$291K Buy
+3,298
New +$293K 0.05% 151

Other funds holding NVS

Endurance Wealth Management's NVS Position: Q4 2020 in Review

Endurance Wealth Management sold out of Novartis (NVS) in Q4 2020, closing a stake of 290 shares — an estimated $25K sold.

Endurance Wealth Management first reported a position in NVS in Q1 2015 and held it in 23 quarters. The position peaked at $760K in Q2 2019. 1,177 funds tracked by Wall St. Rank hold NVS as of Q4 2020.

  • Endurance Wealth Management reported no remaining Novartis position as of Q4 2020 after selling out during the quarter.
  • Endurance Wealth Management sold 290 Novartis shares in Q4 2020, an estimated $25K.
  • Endurance Wealth Management first reported a position in Novartis in Q1 2015 and held it in 23 quarters.
  • Endurance Wealth Management's Novartis position peaked at $760K in Q2 2019.
  • 1,177 funds tracked by Wall St. Rank held Novartis as of Q4 2020.

Based on Endurance Wealth Management's 13F filing for Q4 2020, filed 15 Jan 2021.